Company Overview
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Why Investors Should Care
Generates a return on equity of 32.3%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.0%.
Net profit has compounded at 19.8% per year over the last five years.
Revenue has grown at a 12.7% CAGR over the past five years.
Maintains a net profit margin of 18.3%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.34B (-0.7% YoY); net profit $850.00M.
- Trailing 12 Months Year-on-year growth — revenue +9.4%, earnings -9.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.7%, profit CAGR 19.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.65% |
| 1 Year: | 9.40% |
Compounded Profit Growth
| 5 Years: | 19.80% |
| 1 Year: | -9.40% |
Stock Price Performance
| 1 Year: | +108.74% |
| 6 Months: | +69.83% |
| 3 Months: | +33.55% |
| 1 Month: | +12.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.65 · Neutral
P/E of 39.30 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 32.3%.
- Compounding revenue at 12.7% over 5 years.
- Profit CAGR of 19.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ILMN Illumina, Inc. R3KPHARMA | 211.06 | 39.30 | $31.87B | 0.00% | 15.95% | 32.34% | 12.65% | 19.80% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Dec 2017 | Apr 2018 | Jul 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 598.00M | 662.00M | 714.00M | 778.00M | 782.00M | 830.00M | 853.00M | 867.00M | 846.00M | 838.00M | 907.00M | 953.00M | 859.00M | 633.00M | 794.00M | - | 1.09B | 1.13B | 1.11B | - | 1.22B | 1.16B | 1.11B | - | 1.09B | 1.18B | 1.12B | - | 1.08B | 1.11B | 1.08B | - | 1.04B | 1.06B | 1.08B | - | 1.09B | 1.16B |
| Gross Profit | 426.00M | 419.00M | 368.00M | 434.00M | 482.00M | 542.00M | 538.00M | 575.00M | 597.00M | 590.00M | 584.00M | 573.00M | 648.00M | 662.00M | 619.00M | 428.00M | 526.00M | - | 764.00M | 802.00M | 770.00M | - | 815.00M | 767.00M | 717.00M | - | 655.00M | 732.00M | 684.00M | - | 667.00M | 721.00M | 745.00M | - | 683.00M | 695.00M | 733.00M | - | 721.00M | 770.00M |
| Operating Income | 161.00M | - | 52.00M | 143.00M | 181.00M | - | 218.00M | 227.00M | 241.00M | - | 204.00M | 205.00M | 308.00M | - | 189.00M | 96.00M | 162.00M | - | 193.00M | 187.00M | -545.00M | - | 184.00M | -579.00M | -3.66B | - | -64.00M | -88.00M | -754.00M | - | -111.00M | -1.64B | 741.00M | - | 164.00M | 214.00M | 227.00M | - | 209.00M | 245.00M |
| Net Income | 129.00M | 124.00M | 367.00M | 128.00M | 163.00M | 68.00M | 208.00M | 209.00M | 199.00M | 210.00M | 233.00M | 296.00M | 234.00M | 239.00M | 173.00M | 47.00M | 179.00M | 257.00M | 147.00M | 185.00M | 317.00M | 113.00M | 86.00M | -535.00M | -3.82B | -139.00M | 3.00M | -234.00M | -754.00M | -176.00M | -126.00M | -1.99B | 705.00M | 186.00M | 131.00M | 235.00M | 150.00M | 334.00M | 134.00M | 207.00M |
| Diluted EPS | 0.87 | 0.84 | 2.48 | 0.87 | 1.11 | 0.46 | 1.41 | 1.41 | 1.33 | 1.41 | 1.57 | 1.99 | 1.58 | 1.61 | 1.17 | 0.32 | 1.21 | - | 1.00 | 1.26 | 2.08 | - | 0.55 | -3.40 | -24.26 | - | 0.02 | -1.48 | -4.77 | - | -0.79 | -12.48 | 4.42 | - | 0.82 | 1.49 | 0.98 | - | 0.87 | 1.35 |
| R&D Expense | 126.00M | - | 145.00M | 130.00M | 134.00M | - | 137.00M | 151.00M | 159.00M | - | 169.00M | 166.00M | 151.00M | - | 156.00M | 155.00M | 172.00M | - | 197.00M | 202.00M | 436.00M | - | 323.00M | 327.00M | 325.00M | - | 341.00M | 358.00M | 315.00M | - | 339.00M | 325.00M | 253.00M | - | 252.00M | 247.00M | 229.00M | - | 240.00M | 252.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 573.23M | 666.32M | 902.74M | 1.06B | 1.15B | 1.42B | 1.86B | 2.22B | 2.40B | 2.75B | 3.33B | 3.54B | 3.24B | 4.53B | 4.58B | 4.50B | 4.37B | 4.34B |
| Gross Profit | 353.09M | 453.88M | 601.54M | 709.10M | 773.53M | 911.89M | 1.30B | 1.55B | 1.67B | 1.83B | 2.30B | 2.47B | 2.20B | 3.15B | 2.97B | 2.74B | 2.86B | 2.87B |
| Operating Income | 80.46M | 125.60M | 211.65M | 199.46M | 200.75M | 134.11M | 514.71M | 613.00M | 587.00M | 606.00M | 883.00M | 985.00M | 580.00M | -123.00M | -4.18B | -1.07B | -833.00M | 807.00M |
| Net Income | 39.42M | 72.28M | 124.89M | 86.63M | 151.25M | 125.31M | 353.35M | 462.00M | 463.00M | 726.00M | 826.00M | 1.00B | 656.00M | 762.00M | -4.40B | -1.16B | -1.22B | 850.00M |
| Diluted EPS | 0.30 | 0.53 | 0.87 | 0.62 | 1.13 | 0.90 | 2.37 | 3.10 | 3.07 | 4.92 | 5.56 | 6.74 | 4.45 | 5.04 | -28.00 | -7.34 | -7.69 | 5.45 |
| R&D Expense | 99.96M | 140.62M | 177.95M | 196.91M | 231.03M | 276.74M | 388.06M | 401.00M | 504.00M | 546.00M | 623.00M | 647.00M | 682.00M | 1.19B | 1.32B | 1.35B | 1.17B | 967.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.43B | 1.84B | 2.20B | 2.57B | 3.02B | 3.34B | 3.69B | 4.28B | 5.26B | 6.96B | 7.32B | 7.58B | 15.22B | 12.25B | 10.11B | 6.30B | 6.64B |
| Total Equity | 353.93M | 798.67M | 864.25M | 1.20B | 1.08B | 1.32B | 1.53B | 1.46B | 1.85B | 2.20B | 2.75B | 3.76B | 4.61B | 4.69B | 10.74B | 6.60B | 5.75B | 2.37B | 2.72B |
| Cash & Equivalents | 174.94M | 327.02M | 144.63M | 248.95M | 302.98M | 433.98M | 711.64M | 636.00M | 769.00M | 735.00M | 1.23B | 1.14B | - | - | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - | - | - | 986.78M | 1.02B | 1.06B | 1.18B | 890.00M | 1.14B | 673.00M | - | - | - | - | - |
| Current Liabilities | - | - | 441.24M | 534.52M | 226.92M | 304.57M | 322.06M | 722.16M | 610.49M | 705.00M | 746.00M | 1.80B | 665.00M | 1.24B | 1.09B | 2.77B | 1.57B | 1.55B | 1.58B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 87.88M | 172.19M | 272.57M | 358.14M | 291.87M | 386.42M | 501.27M | 786.00M | 779.00M | 875.00M | 1.14B | 1.05B | 1.08B | 545.00M | 392.00M | 478.00M | 837.00M | 1.08B |
| Investing Cash Flow | -277.25M | -256.57M | -285.05M | -401.00M | -150.01M | -69.65M | -406.62M | -107.00M | -515.00M | -214.00M | -1.81B | 745.00M | -554.00M | -1.07B | -591.00M | -231.00M | -178.00M | -55.00M |
| Financing Cash Flow | 337.67M | -98.86M | 116.47M | 97.02M | -10.76M | -38.72M | -166.75M | -545.00M | -296.00M | -176.00M | 594.00M | -897.00M | -766.00M | -51.00M | 1.00B | -1.21B | -570.00M | -744.00M |
| Capital Expenditure | -59.69M | -52.67M | -49.82M | -77.80M | -68.78M | -79.22M | -106.00M | -143.00M | -260.00M | -310.00M | -296.00M | -209.00M | -189.00M | -208.00M | -286.00M | -195.00M | -128.00M | -148.00M |
| Free Cash Flow | 28.19M | 119.52M | 222.75M | 280.34M | 223.09M | 307.21M | 395.27M | 643.00M | 519.00M | 565.00M | 846.00M | 842.00M | 891.00M | 337.00M | 106.00M | 283.00M | 709.00M | 931.00M |
| Share Buybacks | 70.78M | 175.14M | 44.02M | 570.41M | 82.52M | 50.02M | 237.18M | 274.00M | 249.00M | 251.00M | 201.00M | 324.00M | 736.00M | 0 | 0 | 0 | 116.00M | 742.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 61.6% | 68.1% | 66.6% | 67.2% | 67.4% | 64.2% | 69.7% | 69.8% | 69.5% | 66.4% | 69.0% | 69.6% | 68.0% | 69.7% | 64.8% | 60.9% | 65.4% | 66.1% |
| Operating Margin % | 14.0% | 18.8% | 23.4% | 18.9% | 17.5% | 9.4% | 27.7% | 27.6% | 24.5% | 22.0% | 26.5% | 27.8% | 17.9% | -2.7% | -91.2% | -23.7% | -19.1% | 18.6% |
| Net Margin % | 6.9% | 10.8% | 13.8% | 8.2% | 13.2% | 8.8% | 19.0% | 20.8% | 19.3% | 26.4% | 24.8% | 28.3% | 20.3% | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| ROE % | 4.9% | 8.4% | 10.4% | 8.1% | 11.5% | 8.2% | 24.2% | 25.0% | 21.1% | 26.4% | 22.0% | 21.7% | 14.0% | 7.1% | -66.7% | -20.2% | -51.5% | 31.2% |
| ROCE % | - | 12.7% | 16.2% | 10.1% | 8.9% | 5.0% | 19.7% | 19.9% | 16.4% | 13.4% | 17.1% | 14.8% | 9.1% | -0.9% | -44.1% | -12.5% | -17.5% | 16.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.71% | 19.19M | $4.60B |
| 2 | Capital World Investors | 10.22% | 15.43M | $3.70B |
| 3 | Vanguard Portfolio Management LLC | 4.39% | 6.63M | $1.59B |
| 4 | Vanguard Capital Management LLC | 4.36% | 6.59M | $1.58B |
| 5 | State Street Corporation | 4.31% | 6.51M | $1.56B |
| 6 | WCM Investment Management, LLC | 4.11% | 6.21M | $1.49B |
| 7 | FMR, LLC | 3.00% | 4.52M | $1.08B |
| 8 | AQR Capital Management, LLC | 2.35% | 3.54M | $849.32M |
| 9 | Primecap Management Company | 2.33% | 3.51M | $842.18M |
| 10 | Geode Capital Management, LLC | 1.95% | 2.95M | $706.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ILMN
ILMN Stock Keeps Climbing. Should You Climb On? - Trefis
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOeTRtR015SExGNUNHSXl0c2VNbmdFMkg2Nmt5UG1DM0FtQm55d1JPMlJjMThZRGNZVm9ZTG9iQU1BT0VmODhtZlZUdjRpeFV0QVpCZS1NUkRoZWpjbkdvYVlGMnA4NXRzcW1DczJsYjV6VnBuRm1BaXdEbnRET1BpMTJDRXJoWnJmMERtNV…
Illumina (ILMN) Stock Looks Priced For Growth More Than Value - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxObG4zd3RZUnBoS2FMRTA5eEdaM0JlSHRmcUNGMkl5d0taVGFid2x2OExRZEEwZ0V1WTR2dmFYSXFNZmNzSFpzbVpRYVJVbmFCRnk1ZkpXMnM5bjk1YUFmWGVfa0tDeWp1OS1nRWRqak5OV1A2Y0tlN0hnU3JiZmxsb3NjRmdPSXp5N0o0RV…
Illumina: Priced For Perfection It Hasn't Earned Yet (NASDAQ:ILMN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOWm5JNmg4U1FILTR3bUN3bkxwNW1GYXlONFJvSmxuT19pbUlPVVh6RkNMXzFPeENwUEpmWFphUFdvY0lZcWs4WTRoSG5KYk9tSHRpUDh1ZWtJZlU1ZmZtN01aUEFsdkZGNEp0QWZ6RzliZUsxakxFQ3JwRll4UndNNmpSY00zeFViU2RxLT…
AI Energy Play Bloom Energy Jumps On S&P 500 News - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPNGRkZ0l6U2d3RTg4VjFaTUNSbE5JTzc0YUNMM3ZDNUZwRTEybjZBdzJXVHkxSmpIZTQ0YVFoV1cwaHpuNDVXVTFWUFBFNURQZ3JtcVgyWWhyRDRYb1JZNUVEMzFDWjg1UndzTjdYR1IyYzYtZGRWcDdleDZlc1NMVXlqa2oyWWVvUFpvam…
Illumina Stock Price Forecast. Should You Buy ILMN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE55WHU1OHZQSGZkTUNPS29tajdnbmR6aEN3c1VQU2p3MDVwWExORmgxejN5c2pwa2drZ0tiWFlTdE1faUtvSXFPVg?oc=5" target="_blank">Illumina Stock Price Forecast. Should You Buy ILMN?</a> <f…
Partnership Deal And Rating Upgrade Altering The Investment Case For Illumina (ILMN)? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOb2FBanFQcnMyODdJVU5yV19LakVRZWZfaDl2X1ZHZ1hOVHk0cE84ZVFMTG1xOGxEYkpOUHNRY3RyMm5DNDZXc2F0dXR1OGtlYUxVTEctUHdtRFVoNmM4LXphN1VFWG4zX19ZSWF5SFBFdzBRb3RCOWdNWVhTal9GMDRRNy1rVXFrTDhZNk…
ILMN — Frequently Asked Questions
What is the current share price of Illumina, Inc. (ILMN)?
As of 2026-09-19 21:16 PDT, Illumina, Inc. (ILMN) trades at $211.06 on NasdaqGS. Its 52-week range is $91.00 to $227.69.
What is the market capitalisation of ILMN?
Illumina, Inc. (ILMN) has a market capitalisation of $31.87B on NasdaqGS.
What is the P/E ratio of ILMN?
ILMN trades at a trailing price-to-earnings (P/E) ratio of 39.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 12.75.
What is the return on equity (ROE) of ILMN?
ILMN has a return on equity (ROE) of 32.34%. Its return on capital employed (ROCE) is 15.95%.
Is ILMN a good stock to buy?
This page provides a data-driven analysis of Illumina, Inc. (ILMN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.